{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:22Z","timestamp":1786991962596,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcv.2023.105382","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:13:01Z","timestamp":1674702781000},"page":"105382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-9261","authenticated-orcid":false,"given":"Eloy E.","family":"Ordaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Vergidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund R.","family":"Razonable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Beam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7898","key":"10.1016\/j.jcv.2023.105382_bib0001","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jcv.2023.105382_bib0002","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cmi.2022.05.002","article-title":"Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab","volume":"28","author":"Vellas","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2023.105382_bib0003","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2023.105382_bib0004","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). https:\/\/www.fda.gov\/media\/154701\/download. Accessed 23 Aug 2022."},{"issue":"23","key":"10.1016\/j.jcv.2023.105382_bib0005","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7906","key":"10.1016\/j.jcv.2023.105382_bib0006","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jcv.2023.105382_bib0007","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/j.jinf.2022.07.014","article-title":"Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment","volume":"85","author":"Vellas","year":"2022","journal-title":"J. Infect."},{"key":"10.1016\/j.jcv.2023.105382_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261045","article-title":"Coronavirus resistance database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons","volume":"17","author":"Tzou","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcv.2023.105382_bib0009","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. https:\/\/www.fda.gov\/media\/156152\/download. Accessed 13 Dec 2022."},{"key":"10.1016\/j.jcv.2023.105382_bib0010","doi-asserted-by":"crossref","unstructured":"Yamasoba D., Kosugi Y., Kimura I., et\u00a0al. Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect. Dis.. 20;22(7):942\u2013943, doi:10.1016\/S1473-3099(22)00365-6.","DOI":"10.1016\/S1473-3099(22)00365-6"},{"key":"10.1016\/j.jcv.2023.105382_bib0011","series-title":"SARS-CoV-2 Mutations Analysis, MAb Susceptibility Summary","year":"2022"},{"issue":"2","key":"10.1016\/j.jcv.2023.105382_bib0012","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.kint.2022.05.008","article-title":"Pre-exposure prophylaxis with 300\u00a0mg Evusheld elicits limited neutralizing activity against the Omicron variant","volume":"102","author":"Benotmane","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.jcv.2023.105382_bib0013","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies","author":"Planas","year":"2022","journal-title":"bioRxiv [Preprint]"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:17:18Z","timestamp":1761362238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653223000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":13,"alternative-id":["S1386653223000057"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105382","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105382"}}